KemPharm Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.85
- Today's High:
- $5.14
- Open Price:
- $5.1
- 52W Low:
- $4.05
- 52W High:
- $6.92
- Prev. Close:
- $4.94
- Volume:
- 289386
Company Statistics
- Market Cap.:
- $200.47 million
- Book Value:
- 2.719
- Revenue TTM:
- $10.72 million
- Operating Margin TTM:
- -171.92%
- Gross Profit TTM:
- $26.59 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -8.97%
- Return on Equity TTM:
- -31.24%
Company Profile
KemPharm Inc had its IPO on 2015-04-16 under the ticker symbol KMPH.
The company operates in the Healthcare sector and Pharmaceuticals industry. KemPharm Inc has a staff strength of 24 employees.
Stock update
Shares of KemPharm Inc opened at $5.1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.85 - $5.14, and closed at $4.97.
This is a +0.61% increase from the previous day's closing price.
A total volume of 289,386 shares were traded at the close of the day’s session.
In the last one week, shares of KemPharm Inc have slipped by -11.09%.
KemPharm Inc's Key Ratios
KemPharm Inc has a market cap of $200.47 million, indicating a price to book ratio of 1.6922 and a price to sales ratio of 14.1611.
In the last 12-months KemPharm Inc’s revenue was $10.72 million with a gross profit of $26.59 million and an EBITDA of $-17723000. The EBITDA ratio measures KemPharm Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, KemPharm Inc’s operating margin was -171.92% while its return on assets stood at -8.97% with a return of equity of -31.24%.
In Q4, KemPharm Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 46.3%.
KemPharm Inc’s PE and PEG Ratio
- Forward PE
- 263.1579
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.91 per share while it has a forward price to earnings multiple of 263.1579 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into KemPharm Inc’s profitability.
KemPharm Inc stock is trading at a EV to sales ratio of 9.0534 and a EV to EBITDA ratio of -2.7801. Its price to sales ratio in the trailing 12-months stood at 14.1611.
KemPharm Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $106.60 million
- Total Liabilities
- $15.62 million
- Operating Cash Flow
- $-17555000.00
- Capital Expenditure
- $29000
- Dividend Payout Ratio
- 0%
KemPharm Inc ended 2023 with $106.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $106.60 million while shareholder equity stood at $71.40 million.
KemPharm Inc ended 2023 with $0 in deferred long-term liabilities, $15.62 million in other current liabilities, 3000.00 in common stock, $-320339000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.18 million and cash and short-term investments were $60.88 million. The company’s total short-term debt was $470,000 while long-term debt stood at $0.
KemPharm Inc’s total current assets stands at $104.28 million while long-term investments were $0 and short-term investments were $20.70 million. Its net receivables were $7.82 million compared to accounts payable of $10.26 million and inventory worth $620000.00.
In 2023, KemPharm Inc's operating cash flow was $-17555000.00 while its capital expenditure stood at $29000.
Comparatively, KemPharm Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $4.97
- 52-Week High
- $6.92
- 52-Week Low
- $4.05
- Analyst Target Price
- $22.33
KemPharm Inc stock is currently trading at $4.97 per share. It touched a 52-week high of $6.92 and a 52-week low of $6.92. Analysts tracking the stock have a 12-month average target price of $22.33.
Its 50-day moving average was $5.39 and 200-day moving average was $5.41 The short ratio stood at 5.87 indicating a short percent outstanding of 0%.
Around 1029% of the company’s stock are held by insiders while 1768.7% are held by institutions.
Frequently Asked Questions About KemPharm Inc
Similar Industry Stocks (Pharmaceuticals)
Most Active
Top Gainers
Top Losers
About
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company’s lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.